skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

79 Total results for product and free and sample content found

Strategic Transactions

2019 IPOs Startup Firms Grab Nearly One-Third Of Total Proceeds

Medtech_Insight_CMS_Weighs_Merits_Of_New_Pass_Through_Payments_For_Aquabeam_System_Eluvia_Stents_In_OPPS_Proposal

Last year, a total of 67 biopharma and medtech companies completed initial public offerings (IPOs), raising for $8.55bn combined.

Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Scri...

The tumor-agnostic developer’s toolkit

The tumor-agnostic developer’s toolkit

The tumor-agnostic developer’s toolkit

Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biom...

RNA Targeting Poised To Share The Spotlight With Gene Therapy

As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies.

Topic Cell and gene therapy

Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biom...

Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.

Citeline

Rescuing The Opioid Crisis

Blog

Recent news of the Ohio State ruling on the opioid litigation trial against Johnson & Johnson shed new light on the complex opioid addiction crisis in the US.

Topic Drug development landscape

Trialtrove: 医療用医薬品の臨床試験情報データベース

Clinical Trial Endpoints Made Easy!

Survival_Data_Boost_Lilly_Novartiss_CDK46_Assault_On_Pfizers_Ibrance_In_Metastatic_Breast_Cancer

Trialtrove recently released a major enhancement that indexes primary and secondary endpoints evaluated in clinical trials. 

Topic Drug development landscape

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

mHealth and Research in Oncology

mHealth and Research in Oncology

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biom...

Gene therapy manufacturers

Gene therapy manufacturers

Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor...

Deconstructing the KRAS+ market opportunity

Deconstructing the KRAS+ market opportunity

With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

Topic biopharmaceutical drug-review

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。